Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Aug 29.
Published in final edited form as: Angew Chem Int Ed Engl. 2012 Oct 16;51(47):11686–11698. doi: 10.1002/anie.201203704

A Continuum of Progress: Applications of N-Hetereocyclic Carbene Catalysis in Total Synthesis

Javier Izquierdo 1, Gerri E Hutson 1, Daniel T Cohen 1, Karl A Scheidt 1,*
PMCID: PMC3756610  NIHMSID: NIHMS503917  PMID: 23074146

Abstract

N-Heterocyclic carbene (NHC) catalyzed transformations have emerged as powerful tactics for the construction of complex molecules. Since Stetter’s report in 1975 of the total synthesis of cis-jasmon and dihydrojasmon by using carbene catalysis, the use of NHCs in total synthesis has grown rapidly, particularly over the last decade. This renaissance is undoubtedly due to the recent developments in NHC-catalyzed reactions, including new benzoin, Stetter, homoenolate, and aroylation processes. These transformations employ typical as well as Umpolung types of bond disconnections and have served as the key step in several new total syntheses. This Minireview highlights these reports and captures the excitement and emerging synthetic utility of carbene catalysis in total synthesis.

Keywords: Homogeneous catalysis, natural products, N-heterocyclic carbenes, synthetic methods, total synthesis

1. Introduction

The inspiring structures and potential application of natural products have propelled scientists to pursue the total synthesis of bioactive molecules through the development of new synthetic methods. A current challenge for this highvalue activity is the integration of new catalytic bond-forming tactics and strategies that enhance efficiency and provide rapid access to target compounds. In this regard, N-heterocyclic carbene (NHC) catalysis has emerged as a powerful method in organocatalysis to fashion new bonds with high levels of stereoselectivity through Umpolung as well as normal polarity based transformations. Until recently, total syntheses involving carbene catalysis were rare, presumably because of the restricted substrate scopes of established benzoin and Stetter NHC manifolds and the dearth of different reaction classes, which are now rapidly emerging. In this Minireview, the recent applications of NHC catalysis in the construction of natural products are summarized.

2. NHC-Catalyzed Benzoin Condensations

The coupling between two aldehydes or an aldehyde and ketone, also known as the benzoin condensation, is the most venerable of Umpolung reactions, which is used for the preparation of acyloins.[1] In 1832, Wöhler and von Liebig reported the use of cyanide to promote the benzoin condensation.[2] In 1943, Ugai et al. demonstrated that NHCs generated from the corresponding thiazolium precursor can serve as effective catalysts in this unusual reaction.[3] Since this discovery, N-heterocyclic carbenes have been employed to catalyze numerous benzoin condensation reactions, including those of enolizable aldehydes and ketones, as well as the cross-benzoin reaction.[4] To further enhance the synthetic utility of the benzoin reaction, the research groups of Sheehan,[5] Enders,[6] and others[7] have developed asymmetric variants of this process by using chiral NHCs.

2.1. Synthesis of trans-Resorcylide

trans-Resorcylide (7) is a 12-membered macrocyclic lactone which belongs to a family of naturally occurring benzoic acid derived macrolide plant-growth inhibitors isolated from Penicillium sp. in 1978.[8] In 2007, Mennen and Miller reported a formal synthesis of trans-resorcylide through an NHC-mediated benzoin macrocyclization.[9] Activation of the aliphatic aldehyde by the NHC generated from azolium salt 1 was preferred over the ortho-substituted benzaldehyde, and gave rise to macrolactones of type 5 as the only product. The synthesis began by a five-step reaction sequence to prepare thioether dialdehyde 4 from alcohol 3 and benzoic acid 2. A subsequent intramolecular benzoin condensation afforded macrolactone 5 as a mixture of diastereomers in 21% yield (Scheme 1). The benzylic hydroxy group was subsequently removed through an acylation/deoxygenation sequence, and elimination of the sulfone led to dibenzylated trans-resorcylide 6.[10]

Scheme 1.

Scheme 1

Macrolactonization used by Mennen and Miller in the preparation of trans-resorcylide. Bn=benzyl, DBU=1,8-Diazabicyclo-[5.4.0]undec-7-en.

2.2. Synthesis of (+)-Sappanone B

(+)-Sappanone B (11) is a homoisoflavanoid isolated from the heartwood of Caesalpinia sappan Leguminosae.[11] This 3-hydroxychromanone has inhibitory activity towards xanthine oxidase.[12] In 2007, Takikawa and Suzuki reported the total synthesis of (+)-sappanone B.[13] Ketoaldehyde 9 was obtained in five steps from commercially available 3-methoxysalicylic acid. Aldehyde 9 underwent a smooth intramolecular benzoin reaction in the presence of triazolium salt 8 and triethylamine within 12 h to produce methylated (+)-sappanone B (10) in 92% yield with 95% ee (Scheme 2). The incorporation of the 3,5-trifluoromethyl substituents on the triazolium-derived NHC are notable and were tuned for optimal selectivity for the asymmetric transformation. Demethylation of 10 gave (+)-sappanone B (11) in 59% overall yield over eight steps

Scheme 2.

Scheme 2

Synthesis of (+)-Sappanone B.

2.3. Synthesis of Cassialoin

Cassialoin (17) is an anthrone C-glycoside isolated from the plant extracts of Cassia garrettiana.[14] It is also found in the roots of Rheum emodi[15] and the Chinese herb Rumex dentatus.[16] The unique structural features of cassialoin include a phenolic anthraquinone skeleton stereogenically attached to a β-glycoside. Cassialoin has been identified in in vivo biological studies to inhibit tumor growth and metastasis in mice.[17] In 2007, Suzuki and co-workers reported the first stereoselective total synthesis of cassialoin.[18] The diastereoselective assembly of the anthroquinone skeleton was accomplished by an intramolecular NHC-catalyzed benzoin condensation. The treatment of ketoaldehyde 13 with 10 mol% of thiazolium salt 12 and DBU at 40°C for 2 h gave ketol 14 in 99% yield with excellent diastereoselectivity (Scheme 3). The lithium anion of glycal 15 was added to ketone 14 to afford cis-diol 16 as a single diastereomer. An additional eight steps gave the natural product cassialoin (17). The completion of this synthesis confirmed the originally proposed structure of cassialoin.[14]

Scheme 3.

Scheme 3

Synthesis of cassialoin by Suzuki and co-workers. MOM=methoxymethyl, TIPS=triisopropylsilyl.

2.4. Synthesis of the Kinamycins and the Monomeric Unit of the Lomaiviticin Aglycon

The kinamycins[19] and lomaiviticins A and B[20] are natural products with antibiotic and antitumor activities. These natural compounds are structurally novel, with a diazofluorene group and a densely oxygenated cyclohexane ring. Lomaiviticins are dimers of a diazofluorene structure similar to the kinamycins. Kinamycins A–D were isolated from the fermentation broth of Streptomyces murayamaensis.[19] In 2007, Nicolaou et al. reported a synthesis of kinamycins C, F, and J.[21] An Ullmann coupling between bromide 18 and iodide 19 afforded aldehyde 20 on a multigram scale. Aldehyde 20 underwent a benzoin condensation in the presence of azolium 1 to yield cyclopentanone 21 in 78% yield and with 3:1 d.r. (Scheme 4). A subsequent ten steps afforded diazofluorene 22. A selective hydrolysis or selective manipulations of the acetate led to the three kinamycins (23–25) in yields between 9 and 11% from the Ullmann coupling.

Scheme 4.

Scheme 4

Total synthesis of kinamycins C, F, and J by Nicolaou et al. TBS = tert-butyldimethylsilyl.

Lomaiviticins A (31) and B (32) are dimeric natural products isolated from Micromonospora lomaivitiensis that exhibit impressive antitumor and antibiotic activities against a variety of cancer cell lines and bacteria, respectively. In particular, lomaiviticin A has IC50 values ranging from 0.01 to 98 mm against numerous cancer cell lines.[20] In 2009, Nicolaou et al. reported an enantioselective route to the monomeric unit of lomaiviticin aglycon (30).[22] The structural similarities between the lomaiviticin aglycon and the kinamycins allowed them to apply a similar synthetic approach that was employed for the kinamycins (see above). Unfortunately, the attempted NHC-catalyzed benzoin condensation with bromide 18 (Scheme 4) resulted in the Stetter product as the major component. To circumvent this problem, the synthesis was reengineered by using bromide 27, which has SEM ethers at C7 and C10. These SEM groups would force the OMe group at C11 towards the C4 carbonyl group, thus rotating the bond between the two cyclic systems, and thereby allowing the acyl anion to favor the benzoin pathway. The treatment of ketoaldehyde 28 with NHC generated from azolium salt 1 afforded benzoin product 29 with excellent chemoselectivity (> 20:1 d.r.; Scheme 5). Other more sterically demanding groups afforded lower selectivities or were not compatible with the necessary previous Ullmann coupling step. A subsequent five steps led to lomaiviticin aglycon in 16.5% yield over nine steps.

Scheme 5.

Scheme 5

Synthesis of the lomaiviticins by Nicolaou et al. SEM=2-(trimethylsilyl)ethoxymethyl.

2.5. Synthesis of Seragakinone A

Seragakinone A (39) was isolated from an unidentified marine fungus in symbiosis with rhodophyta Ceradictyon spongiosum,[23] and has shown antifungal and antibacterial activity. This natural product contains a densely oxygenated pentacyclic core with a prenyl group situated in a sterically hindered angular position. In 2011, Suzuki and co-workers reported an enantioselective synthesis of (−)-seragakinone A (39), with two of the key reactions used to fashion the tetracyclic core being benzoin condensations.[24] The synthesis began with a six-step sequence to convert aryl bromide 34 into aldehyde 35. The treatment of aldehyde 35 with triazolium salt 8[25] and triethylamine afforded tetracyclic compound 36 in high yield (86%) with excellent enantioselectivity (99% ee; Scheme 6). Thirteen subsequent steps afforded ketoaldehyde 37. A second benzoin condensation using triazolium salt 33[26] furnished ketol 38 in 90% yield with excellent diastereoselectivity. The stereochemistry of ketol 38 was verified by X-ray crystallographic analysis. Four additional steps furnished seragakinone A (39) in a total of 26 steps and 2.3% overall yield.

Scheme 6.

Scheme 6

Total synthesis of seragakinone A by Suzuki and co-workers.

3. The Stetter Reaction

The conjugate addition of acyl anion equivalents to α,β-unsaturated carbonyl compounds is commonly known as the Stetter reaction.[27] This reaction offers a straightforward route for the synthesis of 1,4-dicarbonyl compounds, which are important intermediates in synthesis.[28] Although there have been significant advances in asymmetric intramolecular Stetter reactions by the research groups of Enders,[29] Rovis,[30] and Hamada,[31] intermolecular Stetter reactions are inherently more challenging and further exploration is still needed. Typically, more activated substrates must be used, such as alkylidene malonates,[32] nitroalkenes,[33] or β,γ-ketoesters,[34] to achieve selective intermolecular variants. In many of these intermolecular variants, self-condensation or benzoin byproducts are common side reactions. Successful strategies to suppress these undesired reactions with thiazolium-derived NHC catalysis include the use of α-keto carboxylates or acylsilanes[35] as acyl anion precursors.[36] This section includes reports of successful total and formal syntheses involving NHC catalysis in Stetter reactions.[37]

3.1. Synthesis of cis-Jasmon and Dihydrojasmon

Naturally occurring cis-jasmon (43) and the related compound dihydrojasmon (44) are used as fragrance agents.[38] In 1975, Stetter and Kuhlmann reported the total syntheses of these two natural products (Scheme 7).[39] The routes involved a thiazolium-catalyzed (12) intermolecular addition of saturated aldehydes 40 or 41 to methyl vinyl ketone 42 and aldol condensation to form cis-jasmon (43) and dihydrojasmon (44). To the best of our knowledge, this report describes the first application of the Stetter reaction in total synthesis.

Scheme 7.

Scheme 7

Synthesis of cis-jasmon and dihydrojasmon by Stetter and Kuhlmann.

3.2. Synthesis of (±)-Hirsutic Acid C

Hirsutic acid C (50) is a tricyclic sesquiterpene and is a highly congested complex natural product with seven stereogenic centers, six of which are contiguous. The members of this family possess both antibiotic and antitumor activity.[40] In a seminal demonstration of the utility of the Stetter reaction to form polycyclic structures in syntheses, Trost et al. reported in 1979 the first stereocontrolled synthesis of (±)-hirsutic acid C (50).[41] The synthesis began with a ten-step reaction sequence to convert cyanocyclohexane 46 into polycyclic aldehyde 47 (Scheme 8). Treatment of aldehyde 47 with 2.3 equivalents of the thiazolium salt 45 and a large excess of triethylamine afforded the tricyclic ketone 48 in 67% yield. Reduction of the ketone in tricycle 48, γ-lactonization, and an ozonolysis/reduction protocol furnished lactone 49, thereby delivering the core of hirsutic acid. A subsequent four-step reaction sequence yielded hirsutic acid C in a total of 19 steps and 3.4% overall yield.

Scheme 8.

Scheme 8

Synthesis of (±)-hirsutic acid C.

3.3. Synthesis of the Core of Atorvastatin

Atorvastatin calcium is a drug that has been marketed under the trade name Lipitor since 1997 by Pfizer. Lipitor is one of the most successful drugs in history and belongs to the statin drug class that is used to control cholesterol levels in the blood by inhibition of the HMG-CoA enzyme. It contains a tetrasubstituted pyrrole with an N-alkyl chain bearing a 1,3-chiral diol and a terminal carboxylic acid (Scheme 9). QSAR studies led to the incorporation of phenyl and phenylamide moieties at positions 3 and 4 to increase the drug activity.[42] The synthesis outlined by Roth et al. involves a Stetter reaction between p-fluorobenzaldehyde (51) and carboxamide 52 to furnish the desired 1,4-diketone 53 in 80% yield. A subsequent optimized Paal–Knorr reaction with heptanoate amine 54 afforded atorvastatin (55).[43] This route is notable given the significant scale of this Umpolung reaction and since it involves fine tuning of the reaction partners to avoid any undesired benzoin reaction of the aldehyde (51).

Scheme 9.

Scheme 9

Synthesis of Atorvastatin (Lipitor).

3.4. Synthesis of Roseophilin

Roseophilin (61) was isolated from the fermentation broth of Streptomyces griseo Viridis.[44] Roseophilin contains an azafulvene moiety conjugated to a pyrrolylfuran and an ansa macrocycle. The potent biological activity and unique structure have made it a popular target for synthesis.[45] In 1999, Harrington and Tius reported a 12-step formal synthesis of roseophilin and obtained the racemic core of 60.[46] Two years later, the authors reported an enantioselective variant. The key step of the synthesis was the formation of cyclopentenone 57 by a Nazarov cyclization reaction. Treatment of unsaturated ketone 57 with two equivalents of 6-heptenal (58), thiazolium 56, and triethylamine afforded the Stetter product 59 in good yield and in favor of the trans isomer (Scheme 10). Ring-closing metathesis, a selective olefin hydrogenation, and a subsequent Knorr reaction afforded the enantiopure roseophilin core 60. An alkylation of the corresponding difuryl compound with the ansa core completed the synthesis of roseophilin (61) in 15 steps and 7% overall yield.[47]

Scheme 10.

Scheme 10

Synthesis of roseophilin by Harrington and Tius. Bz = Benzoyl.

3.5. Synthesis of (±)-trans-Sabinene Hydrate

The natural product trans-sabinene hydrate (66) is a flavor component found in a variety of essential oils.[48] Galopin designed a short and economical synthesis of the natural product, presumably to promote the use of trans-sabinene hydrate as a food additive.[49] Treatment of isovaleraldehyde (62) generated dicarbonyl compound 64 in 82% yield (Scheme 11). A base-promoted aldol cyclization yielded cyclopentenone 65. A subsequent Corey–Chaychovsky reaction and reduction with LiAlH4 provided access to (±)-trans-sabinene hydrate (66) in 28% yield over four steps.

Scheme 11.

Scheme 11

Synthesis of (±)-trans-sabinene hydrate.

3.6. Synthesis of (+)-Monomorine I and Related Natural Products

Indolizidine alkaloid (+)-monomorine I (75) was isolated from the pharaoh ant Monomorium pharaonis L.,[50]and (3R,5S,9S)-3-ethyl-5-methylindolizidine (76) was isolated from the venom of the ant Solenopsis (Diplorhoptrum) conurata.[51]In 2003, Randl and Blechert reported the syntheses of these two compounds. Their approach involved a five-step linear sequence featuring a sequential crossmetathesis and double reductive cyclization reaction as the key steps.[52] The syntheses began with a thiazolium-catalyzed (67) intermolecular Stetter reaction between masked acrolein 5-norbornene-2-carbaldehyde (70) and vinyl ketone 68 or 69 to provide 1,4-diketones 71 and 72 (Scheme 12). A retro-Diels–Alder reaction to fragment the norbornene moiety, followed by an intermolecular cross-metathesis with a Cbzprotected (S)-4-penten-2-amine furnished carbamates 73 and 74. The reductive amination of carbamates 73 and 74 gave natural products 75 and 76 in 35% and 29% overall yield, respectively.

Scheme 12.

Scheme 12

Synthesis of indolizidine alkaloids 75 and 76 by Randl and Blechert. Cbz = carbobenzyloxy.

3.7. Synthesis of Haloperidol

Haloperidol (79) is a widely used antipsychotic and its therapeutic properties have been historically associated with its D2 antagonist activity.[53] In 2004, Grée and co-workers reported a synthesis of haloperidol (79) that relies on an efficient Umpolung approach. The 1,4-dicarbonyl compound 78 was obtained by a Stetter reaction between p-fluorobenzaldehyde (51) and methyl acrylate (77) catalyzed by the thiazolium salt 56 in an ionic liquid (Scheme 13). A subsequent four synthetic steps led to haloperidol in 30% overall yield.[54]

Scheme 13.

Scheme 13

Synthesis of haloperidol (Haldol) by Grée and co-workers. Bmim=butylmethylimidazolium.

3.8. Synthesis of (±)-Platensimycin

Platensimycin (84) has shown in vitro activity against Staphylococcus aureus and Enterococcus faecium.[55]In 2007, Nicolaou and co-workers reported a formal synthesis of (±)-platensimycin,[56] with key bond-forming reactions involving an intramolecular Stetter reaction, a tin-promoted radical cyclization, and a cyclization promoted by trifluoroacetic acid (Scheme 14). The exposure of ketoaldehyde 80 to 1.0 equivalents of azolium 1 and triethylamine provided the corresponding Stetter adduct 81 in 64% yield with excellent diastereoselectivity (20:1 d.r.). Cyclohexenone 81 was converted into tetracycle 82 by formation of a dithiane from the enone and oxidation of the free ketone to the enone followed by a tin-radical cyclization. A subsequent three steps furnished the core structure of (±)-platensimycin (83).[57]

Scheme 14.

Scheme 14

Formal synthesis of (±)-platensimycin by Nicolaou et al. TFA=trifluoroacetic acid.

3.9. Synthesis of Englerin A

Englerin A (89) is a guaiane-type sesquiterpene natural product isolated from the Tanzanian plant Phyllanthus engleri that has shown highly potent and selective cytotoxicity against various renal cancer cell lines at low nanomolar levels.[58] In 2010, Theodorakis and co-workers reported an elegant enantioselective formal synthesis of englerin A (89) through a rhodium(II)-catalyzed [4+3] cycloaddition reaction between diazo ester 85 and 2-isopropyl-5-methylfuran to form the oxa-tricyclic motif of the structure and furnish α-hydroxyenone 86 in three steps.[59]Simple protection of the secondary alcohol as the silyl ether followed by a Stetter reaction with propanal in the presence of thiazolium salt 56 gave diketone 87 as a single diasteroisomer in 75% yield over two steps. A subsequent 10 steps furnished tricyclic substituted furan 88, which is a known intermediate in the synthesis of englerin A by Ma and co-workers,[60] in a 5% yield over the 15 steps (Scheme 15).

Scheme 15.

Scheme 15

Formal synthesis of (−)-englerin A. KHMDS=potassium bis(trimethylsilyl)amide, TES=triethylsilyl.

4. NHC-Homoenolate Equivalents

Homoenolates are synthetically important reactive species that can be used for the construction of both linear and cyclic structures. Although their enolate counterparts can be generated under a relatively large number of catalytic and stoichiometric conditions, there are relatively few general methods to generate homoenolates. Some early reported protocols for the generation of homoenolates require harsh conditions, which limited their synthetic use.[61] In 2004, the research groups of Glorius and Bode independently reported the synthesis of γ-butyrolactones by the homoenolate annulation of aldehydes.[62] This method relies on the catalytic generation of a homoenolate by using an NHC and an amine or alkoxide base. Since those initial reports, this area has undergone tremendous growth and has provided new methods for the highly selective assembly of important structural motifs.[63]

4.1. Formal Synthesis of Salinosporamide A

Salinosporamide A (96) is a secondary metabolite isolated from the marine actinomycete bacteria and has attracted much attention because of its in vitro cytotoxic activity against several tumor cell lines, including HCT-116 human colon carcinoma (IC50 = 1 µm). Significant additional biological activity includes inhibition of the 20S proteasome and proteasomal chymotrypsin-like proteolytic activity (IC50 = 1.3 nM).[64] In 2009, Struble and Bode reported a formal synthesis of salinosporamide through the formation of a γ-butyrolactone by an intramolecular homoenolate annulation of a ketone.[65]This system suffered from many side reactions such as addition of the NHC-enolate or intramolecular aldol reactions. After extensive optimization, these side reactions were supressed, but high diastereoselectivity was not achieved, even by the use of chiral NHC catalysts. Aldehyde 94 was synthesized in five steps from the reported chiral amine. The NHC reaction afforded the desired bicycle 95 in high yield, but with almost negligible diastereoselectivity. The NHC catalyst derived from azolium precursor 90 afforded the best ratio of the desired diastereomer but in only an approximate 1:1 ratio (Scheme 16). The bicyclic lactone (95) is a known intermediate that has been converted into salinosporamide A in eight steps by Lam and co-workers.[66]

Scheme 16.

Scheme 16

Formal synthesis of salinosporamide A.

4.2. Synthesis of Bakkenolides I, J, and S

The first isolation of a bakkane was reported in 1968, and since then over 50 members of this family have been reported.[67] Bakkanes are sesquiterpene natural products containing a cis-fused 5,6-bicyclic core with five contiguous stereocenters around the hydrindane core, including two quaternary carbon atoms and a spiro y-butyrolactone.[68] The bakkenolides have been shown to have antifeedant effects, inhibit platelet aggregation, and to have anticancer activity against a variety of tumor cell lines.[69]

In 2010, our research group reported a highly diastereoselective and enantioselective NHC-catalyzed desymmetrization of 1,3-diketones.[70] This method allowed the assembly of the indane core of bakkenolides, and was deployed as the key step in the synthesis of bakkenolides I, J, and S (Scheme 17). Aldehyde 98 was prepared in two steps from the corresponding diketone by a palladium-catalyzed Tsuji–Trost allylation and subsequent oxidation. Exposure of aldehyde 98 to chiral triazolium 97 and one equivalent of the Hunig base furnished lactone 99 in 69% yield with excellent diastereo- and enantioselectivity. Propargyl ester 100 was obtained in 13 steps from (β-lactone 99. A diastereoselective Mn(OAc)3-promoted-formation of the spiro γ-butyrolactone furnished the undesired epimer 101 of bakkenolide S. A base-initiated retro-aldol/aldol process first reported by Deprés and co-workers[71] allowed for the formation of bakkenolide S (102). The subsequent acylation with the corresponding acid chlorides led to the bakkenolides I and J. Thus, three natural products were synthesized in 20 steps in 2% overall yield, and this study represents the first completed syntheses using carbene-catalyzed homoenolate equivalents.

Scheme 17.

Scheme 17

Synthesis of bakkenolide S. TBAF=tetrabutylammonium fluoride.

4.3. Synthesis of Maremycin B

Maremycin B (106) is a diketopiperazine alkaloid isolated from the culture broth of marine Streptomyces species B9173.[72] In addition to its interesting structure, it has been shown to have anticancer activity. We recently reported the concise and enantioselective synthesis of maremycin B by employing an NHC-homoenolate equivalent addition (Scheme 18).[73] The formation of a spirooxindole was accomplished by the homoenolate annulation of crotonaldehyde (104) and N-methylisatin (103). Lactone 105 was formed in 76% yield and good diastereo- and enantioselectivity, with the necessary enantiopure material obtained by a single recrystallization. A subsequent five-step sequence gave maremycin B (106) in 17% yield over six steps without the need for any protecting groups.

Scheme 18.

Scheme 18

Synthesis of maremycin B by an NHC-catalyzed formal [3+2] annulation

5. NHC-Catalyzed Aroylation Reactions

In 1990, Miyashita et al. reported the carbene-catalyzed nucleophilic aroylation of 4-chloro-1H–pyrazolo-[3,4d]pyrimidines.[74] This reaction employs a NHC-generated acyl anion as the nucleophile in nucleophilic aromatic substitution reactions. Over the past 20 years, Miyashita, Suzuki, and co-workers have developed this reaction into a general method for the synthesis of aroyl compounds.[75]In 2008, they reported the aroylation of functionalized fluorobenzenes with NHC catalyst loadings as low as 1 mol%.[76]‘

5.1. Synthesis of Atroviridin

Atroviridin (112) is an oxygenated xanthone isolated from Garcinia atroviridus Griff.,[77] Recently, Suzuki et al. reported the total synthesis of atroviridin by using his NHC-catalyzed aroylation strategy to assemble the tetracyclic core (Scheme 19).[75e] The treatment of functionalized benzaldehyde 108 and substituted benzene ring 109 with 10 mol% of catalyst 107 and NaH yielded benzophenone 110 in 76% yield which was subsequently converted into triphenol 111 in five steps. A subsequent MnO2 oxidation, followed by an intramolecular Michael addition reaction and demethylation with boron tribromide gave atroviridin in nine steps with a 14% overall yield.

Scheme 19.

Scheme 19

Synthesis of atroviridin by Suzuki et al.

6. NHC-Catalyzed Redox and Oxidative Processes

In addition to the various Umpolung reactions catalyzed by NHCs (e.g., benzoin, Stetter, and homoenolate equivalents), these unusual Lewis bases are also capable of promoting redox (internal or external) reactions involving terminal acylation events.[1c,d,78] Reports by our research group[79] and by Studer and co-workers[80] have demonstrated that the oxidation of the activated alcohol intermediate with metal or organic oxidants allows for the direct conversion of unactivated aldehydes into the corresponding esters. Aldehydes with an α-substituent (e.g., chlorides) have also been employed in this redox process.[81] In addition to esters, other functionalities such as amides[82] and acyl azides[83] have been obtained by this redox NHC method. In addition to these aldehyde-based transformations, Lupton and co-workers reported the first conjugate addition of α,β-unsaturated acyl azoliums.[84] These intermediates have been shown to be excellent conjugate acceptors.[85] These non-Umpolung type of reaction manifolds have added greatly to the synthetic repertoire of carbene catalysis, and new applications of these processes are just now emerging. This section includes reports of total and formal syntheses completed by using NHC catalysis for these non-Umpolung transformations.[86]

6.1. Synthesis of (+)-Davanone

Davanone (116), is a sesquiterpene natural product which exhibits antifungal and antispasmodic activity. It was first isolated from Artemisia pallens in 1968, and is the principle component of davana oil.[87] In 2009, Vosburg and co-workers reported a short total synthesis of (+)-davanone involving an epoxide-opening NHC reaction (Scheme 20).[88] The treatment of α,β-epoxyaldehyde 114 with the thiazolium salt 113 and Hunig’s base triggered an epoxide opening/esterification to afford anti diastereomer 115 in good yield. A palladiumcatalyzed allylic O-alkylation, formation of the Weinreb amide, and Grignard addition furnished (+)-davanone (116) in only seven steps from geranyl acetate.

Scheme 20.

Scheme 20

Total synthesis of (+)-davanone by Vosburg and co-workers.

6.2. Synthesis of (−)-7-Deoxyloganin

(−)-7-Deoxyloganin (120) is a monoterpenoid iridoid, and the majority of these monoterpenoid natural products contain a cis relationship between H5 and H9 in the cyclopentapyran core (Scheme 21).[89] These iridoid natural products exhibit broad biological activity and are key intermediates in alkaloid biosynthesis.[90] Candish and Lupton recently reported the synthesis of (−)-7-deoxyloganin (120) through an interesting NHC-catalyzed reaction. In this reaction, free carbene 117 is used as a nucleophilic catalyst to promote the α,β-unsaturated enol ester rearrangement of 118 to form dihydropyranone 119.[91] Surprisingly, this reaction proceeds in the presence of the methyl ester, even though NHCs are known to activate esters for transesterification.[92] The α,β-unsaturated enol ester 118 was synthesized from 2,5-dimethoxytetrahydrofuran in 13 steps. NHC 117 was identified as the optimal catalyst in terms of the yield and selectivity of the α,β-unsaturated enol ester rearrangement. Four subsequent steps gave (−)-7-deoxyloganin (120) in 18 steps and 0.7% overall yield. In 2011, Candish and Lupton reported a modified synthesis starting from (S)-citronellal. This route allowed access to (−)-7-deoxyloganin (120) in just ten steps with 3.1% overall yield.[93] A well-designed and executed crossover study revealed that this reaction likely proceeds in an intramolecular manner.[93]

Scheme 21.

Scheme 21

Synthesis of (−)-7-deoxyloganin by Candish and Lupton.

6.3. Synthesis of (+)-Dactylolide

(+)-Dactylolide (126) is a cytotoxic 20-membered macrolide isolated from the Vanuatu sponge Dactylospongia sp. which displays modest inhibitory activities towards tumor cell growth in leukemia and ovarian cancer cell lines.[94] Hong and co-workers have very recently reported a total synthesis of (+)-dactylolide (Scheme 22). The synthesis showcased a NHC-catalyzed oxidative macrolactonization reaction to form the 20-membered macrocycle.[95] An 11-step reaction sequence converted 1,3-dithiane-2-ethanol (122) into ω-hydroxy aldehyde 123. Aldehyde 123 underwent an impressive intramolecular oxidative macrolactonization to afford 20-membered lactone 125 in 65% yield. The optimal conditions employed for this macrocyclization were azolium 121, DMAP, and 3,3′,5,5′-tetra-tert-butyldiphenoquinone (124).[96] These reagents are an integration of earlier independent NHC oxidation methods by the research groups of Scheidt[97] and Studer.[80] This transformation is the first example of an NHC-catalyzed oxidative macrolactonization of ω-hydroxy aldehydes. Four additional steps provided (+)-dactylolide (126) in 16 steps with 1.9% overall yield.

Scheme 22.

Scheme 22

NHC-catalyzed macrolactonization towards dactyolide. DMAP=4-dimethylaminopyridine.

7. Summary

Carbene catalysis is a rapidly expanding field that has greatly added to the arsenal of efficient and stereoselective bond-forming reactions over the last decade. This Minireview presents the current examples of benzoin condensations, Stetter reactions, homoenolate reactions, and nucleophilic catalyst reactions that can be used to access complex targets. NHC-catalyzed processes are highly versatile in terms of the different reactivity patterns that can be accessed (Umpolung, enolate, oxidation manifolds), and this organocatalytic strategy has come far since its biomimetic beginnings with pyruvate decarboxylase and Ugai et al. in the early 1940s. The further exploration of NHC catalysis will undoubtedly fuel the continued discovery of new methods and reactions, with future subsequent applications in total synthesis. Further research and focus in this exciting area will undoubtedly lead to additional strategies for the construction of privileged motifs, which will be of great value to the fields of natural products total synthesis and medicine.

Acknowledgments

Financial support for this work was provided in part by NIGMS (GM073072). G.E.H. is supported by an NIGMS Diversity Supplement. D.T.C thanks the ACS Division of Organic Chemistry for a 2011–2012 Graduate Fellowship (sponsored by Organic Syntheses/Organic Reactions).

Biographies

graphic file with name nihms503917b1.gif

Javier Izquierdo obtained his PhD atJaume I University (Castello, Spain) in 2011 under the direction of Prof. Florenci Gonzalez. His research focused on the study of nucleophilic epoxidation reactions and their application in the synthesis of new cysteine protease inhibitors. He is currently a postdoctoral fellow in the group of K. A. Scheidt, where he is exploring dual Lewis base catalysis involving N-heterocyclic carbenes.

graphic file with name nihms503917b2.gif

Daniel T. Cohen conducted undergraduate research with Prof. Iwao Ojima (SUNY Stony Brook/NSF-REU) and with Prof. Preeti Dhar (SUNY New Paltz). In 2008, he joined the laboratory of Professor K. A. Scheidt at Northwestern University, where he has explored annulation strategies in N-heterocyclic carbene catalysis for the development of new reactions and total synthesis. He is currently an ACS Division of Organic Chemistry Graduate Fellow (2011–2012).

graphic file with name nihms503917b3.gif

Gerri E. Hutson studied chemistry at The University of Chicago where she received her PhD under the supervision of Prof. Viresh Rawal. Her research focused on developing new chiral salen complexes. She is currently a postdoctoral fellow in the group of K. A. Scheidt, where she is examining the application of carbene catalysis to synthesis.

graphic file with name nihms503917b4.gif

Karl Scheidt is the Alumnae of Northwestern Teaching Professor and co-director of Northwestern University’s Center for Molecular Innovation and Drug Discovery. His research focuses on the development of new organic methods, particularly the discovery of new Lewis base catalyzed reactions, and the synthesis of bioactive molecules.

References

  • 1.a) Enders D, Balensiefer T. Acc. Chem. Res. 2004;37:534–541. doi: 10.1021/ar030050j. [DOI] [PubMed] [Google Scholar]; b) Johnson JS. Angew. Chem. 2004;116:1348–1350. [Google Scholar]; Angew. Chem. Int. Ed. 2004;43:1326–1328. doi: 10.1002/anie.200301702. [DOI] [PubMed] [Google Scholar]; c) Enders D, Niemeier O, Henseler A. Chem. Rev. 2007;107:5606–5655. doi: 10.1021/cr068372z. [DOI] [PubMed] [Google Scholar]; d) Marion N, Diez-Gonzalez S, Nolan IP. Angew. Chem. 2007;119:3046–3058. doi: 10.1002/anie.200603380. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2007;46:2988–3000. doi: 10.1002/anie.200603380. [DOI] [PubMed] [Google Scholar]; e) Enders D, Narine AA. J. Org. Chem. 2008;73:7857–7870. doi: 10.1021/jo801374j. [DOI] [PubMed] [Google Scholar]; f) Dominguez de Maria P, Shanmuganathan S. Curr. Org. Chem. 2011;15:2083–2097. [Google Scholar]; g) Grossmann A, Enders D. Angew. Chem. Int. Ed. 2012;51:314–325. doi: 10.1002/anie.201105415. [DOI] [PubMed] [Google Scholar]; h) Bugaut X, Glorius F. Chem. Soc. Rev. 2012;41:3511–3522. doi: 10.1039/c2cs15333e. [DOI] [PubMed] [Google Scholar]
  • 2.Wçhler F, Liebig J. Ann. Pharm. 1832;3:249–282. [Google Scholar]
  • 3.Ugai T, Tanaka S, Dokawa S. J. Pharm. 1943;63:269–300. [Google Scholar]
  • 4.a) Dünkelmann P, Kolter-Jung D, Nitsche A, Demir AS, Siegert P, Lingen B, Baumann M, Pohl M, Muller M. J. Am. Chem. Soc. 2002;124:12084–12085. doi: 10.1021/ja0271476. [DOI] [PubMed] [Google Scholar]; b) Enders D, Grossmann A, Huang H, Raabe G. Eur. J. Org. Chem. 2011:4298–4301. [Google Scholar]; c) O’Toole SE, Rose CA, Gundala S, Zeitler K, Connon SJ. J. Org. Chem. 2011;76:347–357. doi: 10.1021/jo101791w. [DOI] [PubMed] [Google Scholar]
  • 5.a) Sheehan J, Hunnemann DH. J. Am. Chem. Soc. 1966;88:3666–3667. [Google Scholar]; b) Sheehan J, Hara T. J. Org. Chem. 1974;39:1196–1199. [Google Scholar]
  • 6.a) Enders D, Breuer K, Teles JH. Helv. Chim. Acta. 1996;79:1217–1221. [Google Scholar]; b) Enders D, Kallfass U. Angew. Chem. 2002;114:1822–1824. doi: 10.1002/1521-3773(20020517)41:10<1743::aid-anie1743>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2002;41:1743–1745. doi: 10.1002/1521-3773(20020517)41:10<1743::aid-anie1743>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]; c) Enders D, Niemeier O, Balensiefer T. Angew. Chem. 2006;118:1491–1495. doi: 10.1002/anie.200503885. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2006;45:1463–1467. doi: 10.1002/anie.200503885. [DOI] [PubMed] [Google Scholar]
  • 7.a) Tagaki W, Tamura Y, Yano Y. Bull. Chem. Soc. Jpn. 1980;53:478–480. [Google Scholar]; b) Takikawa H, Hachisu Y, Bode JW, Suzuki K. Angew. Chem. 2006;118:3572–3574. doi: 10.1002/anie.200600268. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2006;45:3492–3494. doi: 10.1002/anie.200600268. [DOI] [PubMed] [Google Scholar]; c) Chiang PC, Kaeobamrung J, Bode JW. J. Am. Chem. Soc. 2007;129:3520–3521. doi: 10.1021/ja0705543. [DOI] [PubMed] [Google Scholar]; d) Baragwa-nath L, Rose CA, Zeitler K, Connon SJ. J. Org. Chem. 2009;74:9214–9217. doi: 10.1021/jo902018j. [DOI] [PubMed] [Google Scholar]
  • 8.Oyama H, Sassa T, Ikeda M. Agric. Biol. Chem. 1978;42:2407–2409. [Google Scholar]
  • 9.Mennen SM, Miller SJ. J. Org. Chem. 2007;72:5260–5269. doi: 10.1021/jo070676d. [DOI] [PubMed] [Google Scholar]
  • 10.Couladouros EA, Mihou AP, Bouzas EA. Org. Lett. 2004;6:977–980. doi: 10.1021/ol0400037. [DOI] [PubMed] [Google Scholar]
  • 11.Siddaiah V, Rao CV, Venkateswarlu S, Krishnaraju AV, Subbaraju GV. Bioorg. Med. Chem. 2006;14:2545–2551. doi: 10.1016/j.bmc.2005.11.031. [DOI] [PubMed] [Google Scholar]
  • 12.Nguyen MTT, Awale S, Tezuka Y, Le Tran Q, Kadota S. Chem. Pharm. Bull. 2005;53:984–988. doi: 10.1248/cpb.53.984. [DOI] [PubMed] [Google Scholar]
  • 13.Takikawa H, Suzuki K. Org. Lett. 2007;9:2713–2716. doi: 10.1021/ol070929p. [DOI] [PubMed] [Google Scholar]
  • 14.a) Hata K, Kozawa M, Baba K. Chem. Pharm. Bull. 1976;24:1688–1689. [Google Scholar]; b) Hata K, Baba K, Kozawa M. Chem. Pharm. Bull. 1978;26:3792–3797. [Google Scholar]
  • 15.Krenn L, Pradhan R, Presser A, Reznicek G, Kopp B. Chem. Pharm. Bull. 2004;52:391–393. doi: 10.1248/cpb.52.391. [DOI] [PubMed] [Google Scholar]
  • 16.Zhu JJ, Zhang CF, Zhang MA, Bligh SWA, Yang L, Wang ZM, Wang ZT. J. Chromatogr. A. 2010;1217:5384–5388. doi: 10.1016/j.chroma.2010.05.039. [DOI] [PubMed] [Google Scholar]
  • 17.Kimura Y, Sumiyoshi M, Taniguchi M, Baba K. Cancer Sci. 2008;99:2336–2348. doi: 10.1111/j.1349-7006.2008.00938.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Koyama Y, Yamaguchi R, Suzuki K. Angew. Chem. 2008;47:1084–1087. doi: 10.1002/anie.200704625. [DOI] [PubMed] [Google Scholar]
  • 19.a) Ito S, Matsuya T, Omura S, Otani M, Nakagawa A, Takeshim H, Iwai Y, Ohtani M, Hata T. J. Antibiot. 1970;23:315–317. doi: 10.7164/antibiotics.23.315. [DOI] [PubMed] [Google Scholar]; b) Hata T, Omura S, Iwai Y, Nakagawa A, Otani M, Ito S, Matsuya T. J. Antibiot. 1971;24:353–359. doi: 10.7164/antibiotics.24.353. [DOI] [PubMed] [Google Scholar]; c) Furusaki A, Watanabe T, Hata T, Omura S, Nakagawa A, Matsui M. Isr. J. Chem. 1972;10:173–183. [Google Scholar]; d) Omura S, Nakagawa A, Yamada H, Hata T, Furusaki A, Watanabe T. Chem. Pharm. Bull. 1973;21:931–940. doi: 10.1248/cpb.21.931. [DOI] [PubMed] [Google Scholar]
  • 20.He HY, Ding WD, Bernan VS, Richardson AD, Ireland CM, Greenstein M, Ellestad GA, Carter GT. J. Am. Chem. Soc. 2001;123:5362–5363. doi: 10.1021/ja010129o. [DOI] [PubMed] [Google Scholar]
  • 21.Nicolaou KC, Li HM, Nold AL, Pappo D, Lenzen A. J. Am. Chem. Soc. 2007;129:10356–10357. doi: 10.1021/ja074297d. [DOI] [PubMed] [Google Scholar]
  • 22.Nicolaou KC, Nold AL, Li HM. Angew. Chem. 2009;121:5974–5977. [Google Scholar]; Angew. Chem. Int. Ed. 2009;48:5860–5863. doi: 10.1002/anie.200902509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.a) Shigemori H, Komatsu K, Mikami Y, Kobayashi J. Tetrahedron. 1999;55:14925–14930. [Google Scholar]; b) Komatsu K, Shigemori H, Shiro M, Kobayashi J. Tetrahedron. 2000;56:8841–8844. [Google Scholar]
  • 24.Takada A, Hashimoto Y, Takikawa H, Hikita K, Suzuki K. Angew. Chem. 2011;123:2345–2349. doi: 10.1002/anie.201006528. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2011;50:2297–2301. doi: 10.1002/anie.201006528. [DOI] [PubMed] [Google Scholar]
  • 25.Takikawa H, Suzuki K. Org. Lett. 2007;9:2713–2716. doi: 10.1021/ol070929p. [DOI] [PubMed] [Google Scholar]
  • 26.Thomson JE, Rix K, Smith AD. Org. Lett. 2006;8:3785–3788. doi: 10.1021/ol061380h. [DOI] [PubMed] [Google Scholar]
  • 27.a) Stetter H, Schrecke M. Angew. Chem. 1973;85:89. [Google Scholar]; Angew. Chem. Int. Ed. Engl. 1973;12:81. [Google Scholar]; b) Stetter H, Schrecken-berg M, Wiemann K. Chem. Ber. 1976;109:541–545. [Google Scholar]; c) Stetter H, Ramsch RY, Kuhlmann H. Synthesis. 1976:733–735. [Google Scholar]; d) Stetter H, Rajh B. Chem. Ber. 1976;109:534–540. [Google Scholar]; e) Stetter H, Kuhlmann H. Chem. Ber. 1976;109:3426–3431. [Google Scholar]
  • 28.a) Jones TH, Blum MS, Fales HM. Tetrahedron Lett. 1980;21:1701–1704. [Google Scholar]; b) El-Hajj T, Martin JC, Descotes G. J. Heterocycl. Chem. 1983;20:233–235. [Google Scholar]; c) Wynberg H, Metselaar J. Synth. Commun. 1984;14:1–9. [Google Scholar]; d) Perrine DM, Kagan J, Huang DB, Zeng K, Teo BK. J. Org. Chem. 1987;52:2213–2216. [Google Scholar]; e) Raghavan S, Anuradha K. Synlett. 2003:711–713. [Google Scholar]
  • 29.a) Enders D. Stereoselective Synthesis. Springer, Heidelberg: 1993. p. 63. [Google Scholar]; b) Enders D, Bockstiegel B, Dyker H, Jelgelka U, Kipphardt H, Kownatka D, Kuhlmann H, Mannes D, Tiebes J, Papadopoulos K. Dechema-Monographies. Vol. 129. Wiley- VCH: Weinheim; 1993. p. 209. [Google Scholar]; c) Enders D, Breuer K. Comprehensive Asymmetric Catalysis. Springer, Berlin: 1999. pp. 1093–1104. [Google Scholar]
  • 30.Moore JL, Kerr MS, Rovis T. Tetrahedron. 2006;62:11477–11482. [Google Scholar]
  • 31.Nakamura T, Hara O, Tamura T, Makino K, Hamada Y. Synlett. 2005:155–157. [Google Scholar]
  • 32.a) Liu Q, Perreault S, Rovis T. J. Am. Chem. Soc. 2008;130:14066–14067. doi: 10.1021/ja805680z. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Liu Q, Rovis T. Org. Lett. 2009;11:2856–2859. doi: 10.1021/ol901081a. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Jousseaume T, Wurz NE, F Glorius. Angew. Chem. 2011;123:1446–1450. doi: 10.1002/anie.201006548. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2011;50:1410–1414. doi: 10.1002/anie.201006548. [DOI] [PubMed] [Google Scholar]
  • 33.a) DiRocco DA, Oberg KM, Dalton DM, Rovis T. J. Am. Chem. Soc. 2009;131:10872–10874. doi: 10.1021/ja904375q. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) DiRocco DA, Rovis T. J. Am. Chem. Soc. 2011;133:10402–10405. doi: 10.1021/ja203810b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Sánchez-Larios E, Thai K, F Bilodeau, Gravel M. Org. Lett. 2011;13:4942–4945. doi: 10.1021/ol202040b. [DOI] [PubMed] [Google Scholar]
  • 35.Mattson AE, Bharadwaj AR, Scheidt KA. J. Am. Chem Soc. 2004;126:2314–2315. doi: 10.1021/ja0318380. [DOI] [PubMed] [Google Scholar]
  • 36.Myers MC, Bharadwaj AR, Milgram BC, Scheidt KA. J. Am. Chem. Soc. 2005;127:14675–14680. doi: 10.1021/ja0520161. [DOI] [PubMed] [Google Scholar]
  • 37.A NHC-catalyzed Stetter reaction was employed in the construction of FD-838, but completion of the total synthesis has not been reported to date: A. Orellana, T. Rovis. Chem. Commun. 2008:730–732. doi: 10.1039/b716445a. [DOI] [PubMed] [Google Scholar]
  • 38.a) Treff W, Werner H. Ber. Dtsch. Chem. Ges. 1933;66:1521–1527. [Google Scholar]; b) Ruzicka L, Lardon F, Treadwell P. Helv. Chim. Acta. 1943;26:673–679. [Google Scholar]
  • 39.Stetter H, Kuhlmann H. Synthesis. 1975:379–380. [Google Scholar]
  • 40.a) Comer FW, Trotter J. J. Chem. Soc. B. 1966:11–18. [Google Scholar]; b) Comer FW, Mccapra F, Qureshi IH, Scott AI. Tetrahedron. 1967;23:4761–4768. doi: 10.1016/s0040-4020(01)92573-6. [DOI] [PubMed] [Google Scholar]; c) Feline TC, Mellows G, Jones RB, Phillips L. J. Chem. Soc. Chem. Commun. 1974:63–64. [PubMed] [Google Scholar]
  • 41.Trost BM, Shuey CD, F Dininno, Mcelvain SS. J. Am.Chem. Soc. 1979;101:1284–1285. [Google Scholar]
  • 42.Roth BD, Blankley CJ, Chucholowski AW, Ferguson E, Hoefle ML, Ortwine DF, Newton RS, Sekerke CS, Sliskovic DR, Stratton CD, Wilson MW. J. Med. Chem. 1991;34:357–366. doi: 10.1021/jm00105a056. [DOI] [PubMed] [Google Scholar]
  • 43.Baumann KL, Butler DE, Deering CF, Mennen KE, Millar A, Nanninga TN, C WPalmer, Roth BD. Tetrahedron Lett. 1992;33:2283–2284. [Google Scholar]
  • 44.Hayakawa Y, Kawakami K, Seto H, Furihata K. Tetrahedron Lett. 1992;33:2701–2704. [Google Scholar]
  • 45.Fiirstner A, Reinecke K, Prinz H, Waldmann H. ChemBioChem. 2004;5:1575–1579. doi: 10.1002/cbic.200400135. [DOI] [PubMed] [Google Scholar]
  • 46.Harrington PE, Tius MA. Org. Lett. 1999;1:649–651. doi: 10.1021/ol990124k. [DOI] [PubMed] [Google Scholar]
  • 47.Harrington PE, Tius MA. J. Am. Chem. Soc. 2001;123:8509–8514. doi: 10.1021/ja011242h. [DOI] [PubMed] [Google Scholar]
  • 48.a) W Daly J, Green FC, Eastman RH. J. Am. Chem. Soc. 1958;80:6330–6336. [Google Scholar]; b) Karasawa D, Shimizu S. Agric. Biol. Chem. 1978;42:433–437. [Google Scholar]; c) Novak J, Bitsch C, Langbehn J, F Pank, Skoula M, Gotsiou Y, Franz CM. Biochem. Syst. Ecol. 2000;28:697–704. doi: 10.1016/s0305-1978(99)00098-8. [DOI] [PubMed] [Google Scholar]
  • 49.Galopin CC. Tetrahedron Lett. 2001;42:5589–5591. [Google Scholar]
  • 50.Ritter FJ, Rotgans IEM, Talman E, Verwiel PEJ, F Stein. Experientia. 1973;29:530–531. [Google Scholar]
  • 51.Jones TH, Highet RJ, Blum MS, Fales HM. J. Chem. Ecol. 1984;10:1233–1249. doi: 10.1007/BF00988551. [DOI] [PubMed] [Google Scholar]
  • 52.Randl S, Blechert S. J. Org. Chem. 2003;68:8879–8882. doi: 10.1021/jo0346095. [DOI] [PubMed] [Google Scholar]
  • 53.a) Gerle B. Acta Psychiatr. Scand. 1964;40:65–76. doi: 10.1111/j.1600-0447.1964.tb05735.x. [DOI] [PubMed] [Google Scholar]; b) Itil TM. Clin. Pharmacol. Ther. 1972;13:141. [Google Scholar]; c) Janzen G, Moleman P. Pharmacopsychiatry. 1988;21:62. [Google Scholar]; d) Allan ER, Sison CE, Alpert M, Connolly B, Crichton J. Psychopharmacol. Bull. 1998;34:71–74. [PubMed] [Google Scholar]; e) Jakovcevska-Kujundziska M, Filovska V, Lazarova V, Serafimova T. Eur. Neuropsychopharmacol. 2002;12:330. [Google Scholar]; f) Lyles-Eggleston M, Altundas R, Xia J, Sikazwe DMN, Fan P, Yang Q, Li S, Zhang W, Zhu X, Schmidt AW, Vanase-Frawley M, Shrihkande A, Villalobos A, Borne RF, Ablordeppey SY. J. Med. Chem. 2004;47:497–508. doi: 10.1021/jm0301033. [DOI] [PubMed] [Google Scholar]; g) Barbui C, Accordini S, Nose M, Stroup S, Purgato M, F Girlanda, Esposito E, Veronese A, Tansella M, Cipriani A, et al. J. Clin. Psychopharmacol. 2011;31:266–273. [Google Scholar]
  • 54.Anjaiah S, Chandrasekhar S, Gree R. Adv. Synth. Catal. 2004;346:1329–1334. [Google Scholar]
  • 55.Diez MT, F Vicente FPelaez, Young K, Wang J. J. Am. Chem. Soc. 2006;128:11916–11920. doi: 10.1021/ja062232p. [DOI] [PubMed] [Google Scholar]; b) Wang J, Soisson SM, Young K, W Shoop, Kodali S, Galgoci A, Painter R, G Parthasarathy Y, Tang S, Cummings R, Ha S, Dorso K, Motyl M, Jayasuriya H, Ondeyka J, Herath K, C WZhang, Hernandez L, Allocco J, Basilio A, Tormo JR, Genilloud O, Vicente F, Pelaez F, Colwell L, Lee SH, Michael B, Felcetto T, C Gill, Silver LL, Hermes JD, Bartizal K, Barrett J, Schmatz D, W Becker J, Cully D, Singh SB. Nature. 2006;441:358–361. doi: 10.1038/nature04784. [DOI] [PubMed] [Google Scholar]
  • 56.C Nicolaou K, Y FTang, Wang JH. Chem. Commun. 2007:1922–1923. doi: 10.1039/b704589a. [DOI] [PubMed] [Google Scholar]
  • 57.Nicolaou KC, Li A, Edmonds DJ. Angew. Chem. 2006;118:7244–7248. [Google Scholar]; Angew. Chem. Int. Ed. 2006;45:7086–7090. doi: 10.1002/anie.200603892. [DOI] [PubMed] [Google Scholar]
  • 58.Ratnayake R, Covell D, T TRansom, Gustafson KR, Beutler JA. Org. Lett. 2009;11:57–60. doi: 10.1021/ol802339w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Xu J, Caro-Diaz EJE, Theodorakis EA. Org. Lett. 2010;12:3708–3711. doi: 10.1021/ol1015652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Zhou QH, Chen XF, Ma DW. Angew. Chem. 2010;122:3591–3594. [Google Scholar]; Angew. Chem. Int. Ed. 2010;49:3513–3516. doi: 10.1002/anie.201000888. [DOI] [PubMed] [Google Scholar]
  • 61.a) Nakamura E, Kuwajima I. J. Am. Chem. Soc. 1984;106:3368–3370. [Google Scholar]; b) Oshino H, Nakamura E, Kuwajima I. J. Org. Chem. 1985;50:2802–2804. [Google Scholar]; c) Nakamura E, Kuwajima I. Tetrahedron Lett. 1986;27:83–86. [Google Scholar]; d) Nakamura E, Aoki S, Sekiya K, Oshino H, Kuwajima I. J. Am. Chem. Soc. 1987;109:8056–8066. [Google Scholar]; e) DiMauro E, Fry AJ. Tetrahedron Lett. 1999;40:7945–7949. [Google Scholar]
  • 62.a) Burstein C, Glorius F. Angew. Chem. 2004;116:6331–6334. doi: 10.1002/anie.200461572. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2004;43:6205–6208. doi: 10.1002/anie.200461572. [DOI] [PubMed] [Google Scholar]; b) Sohn SS, Rosen EL, W Bode J. J. Am. Chem. Soc. 2004;126:14370–14371. doi: 10.1021/ja044714b. [DOI] [PubMed] [Google Scholar]
  • 63.For selected references, seeChan A, Scheidt KA. Org. Lett. 2005;7:905–908. doi: 10.1021/ol050100f. V Nair, Vellalath S, Poonoth M, Mohan R, Suresh E. Org. Lett. 2006;8:507–509. doi: 10.1021/ol052926n. V Nair, Vellalath S, Poonoth M, Suresh E. J. Am. Chem. Soc. 2006;128:8736–8737. doi: 10.1021/ja0625677. Chan A, Scheidt KA. J. Am. Chem. Soc. 2007;129:5334–5335. doi: 10.1021/ja0709167. He M, Bode JW. J. Am. Chem. Soc. 2008;130:418–419. doi: 10.1021/ja0778592. Phillips EM, Reynolds TE, Scheidt KA. J. Am. Chem. Soc. 2008;130:2416–2417. doi: 10.1021/ja710521m. Chan A, Scheidt KA. J. Am. Chem. Soc. 2008;130:2740–2741. doi: 10.1021/ja711130p. Rommel M, Fukuzumi T, Bode JW. J. Am. Chem. Soc. 2008;130:17266–17267. doi: 10.1021/ja807937m. Maki BE, Chan A, Scheidt KA. Synthesis. 2008:1306–1315. doi: 10.1055/s-2008-1072516. Maki BE, Patterson EV, Cramer CJ, Scheidt KA. Org. Lett. 2009;11:3942–3945. doi: 10.1021/ol901545m. Raup DEA, Cardinal-David B, Holte D, Scheidt KA. Nat. Chem. 2010;2:766–771. doi: 10.1038/nchem.727. Cohen DT, Cardinal-David B, Roberts JM, Sarjeant AA, Scheidt KA. Org. Lett. 2011;13:1068–1071. doi: 10.1021/ol103112v. Cohen DT, Cardinal-David B, Scheidt KA. Angew. Chem. 2011;123:1716–1720. doi: 10.1002/anie.201005908. Angew. Chem. Int. Ed. 2011;50:1678–1682. doi: 10.1002/anie.201005908. for recent reviews of NHC-homoenolate equivalents, seePhillips EM, Chan A, Scheidt KA. Aldrichimica Acta. 2009;42:55–66. V Nair, Menon RS, Biju AT, Sinu CR, Paul RR, Jose A, V Sreekumar. Chem. Soc. Rev. 2011;40:5336–5346. doi: 10.1039/c1cs15139h.
  • 64.Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Angew. Chem. 2003;115:369–371. doi: 10.1002/anie.200390115. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2003;42:355–357. [Google Scholar]
  • 65.Struble JR, Bode JW. Tetrahedron. 2009;65:4957–4967. doi: 10.1016/j.tet.2009.03.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Margalef IV, Rupnicki L, Lam HW. Tetrahedron. 2008;64:7896–7901. [Google Scholar]
  • 67.a) N Abe, Onoda R, Shirahat K, T Kato, C Woods M, Y Kitahara. Tetrahedron Lett. 1968:369–373. [Google Scholar]; b) Wu TS, Kao MS, Wu PL, Lin FW, Shi LS, Liou MJ, Li CY. Chem. Pharm. Bull. 1999;47:375–382. doi: 10.1248/cpb.47.375. [DOI] [PubMed] [Google Scholar]
  • 68.a) Silva LF. Synthesis. 2001:671–689. [Google Scholar]; b) Brocksom TJ, Brocksom U, Constantino MG. Quim. Nova. 2008;31:937–941. [Google Scholar]
  • 69.a) Jamieson GR, Reid EH, Turner BP, Jamieson AT. Phytochemistry. 1976;15:1713–1715. [Google Scholar]; b) Kano K, Hayashi K, Mitsuhashi H. Chem. Pharm. Bull. 1982;30:1198–1203. [Google Scholar]
  • 70.Phillips EM, Roberts JM, Scheidt KA. Org. Lett. 2010;12:2830–2833. doi: 10.1021/ol100938j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.a) Greene AE, F Coelho, Depres JP, Brocksom TJ. Tetrahedron Lett. 1988;29:5661–5662. [Google Scholar]; b) Hamelin O, Wang Y, Depres JP, Greene AE. Angew. Chem. 2000;112:4484–4486. doi: 10.1002/1521-3773(20001201)39:23<4314::AID-ANIE4314>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]; Angew. Chem. Int. Ed. 2000;39:4314–4316. doi: 10.1002/1521-3773(20001201)39:23<4314::AID-ANIE4314>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 72.a) W Balk-Bindseil, Helmke E, Weyland H, Laatsch H. Liebigs Ann. 1995:1291–1294. [Google Scholar]; b) Tang YQ, Sattler I, Thiericke R, Grabley S, Feng XZ. Eur. J. Org. Chem. 2001:261–267. [Google Scholar]
  • 73.Dugal-Tessier J, O’Bryan EA, Schroeder TBH, Cohen DT, Scheidt KA. Angew. Chem. Int. Ed. 2012;51:4963–4967. doi: 10.1002/anie.201201643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Miyashita A, Matsuda H, Iijima C, Higashino T. Chem. Pharm. Bull. 1990;38:1147–1152. [Google Scholar]
  • 75.a) Miyashita A, Matsuda H, Iijima C, Higashino T. Chem. Pharm. Bull. 1992;40:43–48. [Google Scholar]; b) Miyashita A, Matsuda H, T Higashino. Chem. Pharm. Bull. 1992;40:2627–2631. [Google Scholar]; c) Miyashita A, Matsuda H, Y Suzuki, Iwamoto K, T Higashino. Chem. Pharm. Bull. 1994;42:2017–2022. [Google Scholar]; d) Y Suzuki TToyota, Miyashita A, Sato M. Chem. Pharm. Bull. 2006;54:1653–1658. doi: 10.1248/cpb.54.1653. [DOI] [PubMed] [Google Scholar]; e) Suzuki Y, Fukuta Y, Ota S, Kamiya M, Sato M. J. Org. Chem. 2011;76:3960–3967. doi: 10.1021/jo200303c. [DOI] [PubMed] [Google Scholar]
  • 76.Y Suzuki, Ota S, Y Fukuta YUeda, Sato M. J. Org. Chem. 2008;73:2420–2423. doi: 10.1021/jo7023569. [DOI] [PubMed] [Google Scholar]
  • 77.Kosin J, Ruangrungsi N, Ito C, Furukawa H. Phytochemistry. 1998;47:1167–1168. [Google Scholar]
  • 78.a) Castells J, Llitjos H, Morenomanas M. Tetrahedron Lett. 1977;18:205–206. [Google Scholar]; b) Inoue H, Higashiura K. J. Chem. Soc. Chem. Commun. 1980:549–550. [Google Scholar]; c) Tam SW, Jimenez L, F Diederich. J. Am. Chem. Soc. 1992;114:1503–1505. [Google Scholar]; d) Miyashita A, Y Suzuki, Nagasaki I, C Ishiguro, Iwamoto K, T Higashino. Chem. Pharm. Bull. 1997;45:1254–1258. [Google Scholar]; e) Chan A, Scheidt KA. J. Am. Chem. Soc. 2006;128:4558–4559. doi: 10.1021/ja060833a. [DOI] [PubMed] [Google Scholar]; f) Maki BE, Chan A, Phillips EM, Scheidt KA. Org. Lett. 2007;9:371–374. doi: 10.1021/ol062940f. [DOI] [PubMed] [Google Scholar]
  • 79.Maki BE, Scheidt KA. Org. Lett. 2008;10:4331–4334. doi: 10.1021/ol8018488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.De Sarkar S, Grimme S, Studer A. J. Am. Chem. Soc. 2010;132:1190–1191. doi: 10.1021/ja910540j. [DOI] [PubMed] [Google Scholar]
  • 81.a) Reynolds NT, deAlaniz JR, T Rovis. J. Am. Chem. Soc. 2004;126:9518–9519. doi: 10.1021/ja046991o. [DOI] [PubMed] [Google Scholar]; b) Chow KYK, Bode JW. J. Am Chem. Soc. 2004;126:8126–8127. doi: 10.1021/ja047407e. [DOI] [PubMed] [Google Scholar]; c) Sohn S, Bode JW. Angew. Chem. 2006;118:6167–6170. [Google Scholar]; Angew. Chem. Int. Ed. 2006;45:6021–6024. doi: 10.1002/anie.200601919. [DOI] [PubMed] [Google Scholar]
  • 82.a) Vora HU, T Rovis. J. Am. Chem. Soc. 2007;129:13796–13797. doi: 10.1021/ja0764052. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) W Bode J, Sohn SS. J. Am. Chem. Soc. 2007;129:13798–13799. doi: 10.1021/ja0768136. [DOI] [PubMed] [Google Scholar]; c) Thai K, Wang L, Dudding T, Bilodeau F, Gravel M. Org. Lett. 2010;12:5708–5711. doi: 10.1021/ol102536s. [DOI] [PubMed] [Google Scholar]; d) Kuwano S, Harada S, Oriez R, Yamada K. Chem. Commun. 2012;48:145–147. doi: 10.1039/c1cc15539c. [DOI] [PubMed] [Google Scholar]
  • 83.a) Vora HU, Moncecchi JR, Epstein O, Rovis T. J. Org. Chem. 2008;73:9727–9731. doi: 10.1021/jo8020055. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) De Sarkar S, Studer A. Org. Lett. 2010;12:1992–1995. doi: 10.1021/ol1004643. [DOI] [PubMed] [Google Scholar]
  • 84.Ryan SJ, Candish L, Lupton DW. J. Am. Chem. Soc. 2009;131:14176–14177. doi: 10.1021/ja905501z. [DOI] [PubMed] [Google Scholar]
  • 85.a) De Sarkar S, Studer A. Angew. Chem. 2010;2010;122:9452–9455. [Google Scholar]; Angew. Chem. Int. Ed. 49:9266–9269. [Google Scholar]; b) Kaeobamrung J, Mahatthananchai J, Zheng PG, Bode JW. J. Am. Chem. Soc. 2010;132:8810–8812. doi: 10.1021/ja103631u. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Sun FG, Sun LH, Ye S. Adv. Synth. Catal. 2011;353:3134–3138. [Google Scholar]; d) Biswas A, De Sarkar S, Frohlich R, Studer A. Org. Lett. 2011;13:4966–4969. doi: 10.1021/ol202108a. [DOI] [PubMed] [Google Scholar]; e) Wanner B, Mahatthananchai J, Bode JW. Org. Lett. 2011;13:5378–5381. doi: 10.1021/ol202272t. [DOI] [PubMed] [Google Scholar]
  • 86.An approach employing an NHC-catalyzed macrocyclization for the synthesis of largazole has been reported, see Wang B, Forsyth CJ. Synthesis. 2009:2873–2880. Wang B, Huang PH, Chen CS, Forsyth CJ. J. Org. Chem. 2011;76:1140–1150. doi: 10.1021/jo102478x. Unfortunately, the ultimately successful route did not use this carbene-catalyzed transformation
  • 87.a) Sipma G, Vanderwa B. Recl. Trav. Chim. 1968;87:715–720. [Google Scholar]; b) Vajs V, Trifunovic S, Janackovic P, Sokovic M, Milpsavljevic S, Tesevic V. J. Serb. Chem. Soc. 2004;69:969–972. [Google Scholar]
  • 88.Morrison KC, Litz JP, Scherpelz KP, Dossa PD, Vosburg DA. Org. Lett. 2009;11:2217–2218. doi: 10.1021/ol900697w. [DOI] [PubMed] [Google Scholar]
  • 89.a) El-Naggar LJ, Beal JL. J. Nat. Prod. 1980;43:649–707. doi: 10.1021/np50012a001. [DOI] [PubMed] [Google Scholar]; b) Boros CA, Stermitz FR. J. Nat. Prod. 1991;54:1173–1246. [Google Scholar]; c) Dinda B, Debnath S, Harigaya Y. Chem. Pharm. Bull. 2007;55:159–222. doi: 10.1248/cpb.55.159. [DOI] [PubMed] [Google Scholar]
  • 90.a) Tietze LF. Angew. Chem. 1983;95:840–853. [Google Scholar]; Angew. Chem. Int. Ed. Engl. 1983;22:828–841. [Google Scholar]; b) Tundis R, Loizzo MR, Menichini F, Statti GA, Menichini F. Mini-Rev. Med. Chem. 2008;8:399–420. doi: 10.2174/138955708783955926. [DOI] [PubMed] [Google Scholar]; c) Dinda B, Chowdhury DR, Mohanta BC. Chem. Pharm. Bull. 2009;57:765–796. doi: 10.1248/cpb.57.765. [DOI] [PubMed] [Google Scholar]
  • 91.Candish L, Lupton DW. Org. Lett. 2010;12:4836–4839. doi: 10.1021/ol101983h. [DOI] [PubMed] [Google Scholar]
  • 92.Rong Z-Q, Zhang W, Yang G-Q, You S-L. Curr. Org. Chem. 2011;15:3077–3090. [Google Scholar]
  • 93.Candish L, Lupton DW. Org. Biomol. Chem. 2011;9:8182–8189. doi: 10.1039/c1ob05953j. [DOI] [PubMed] [Google Scholar]
  • 94.Cutignano A, Bruno I, Bifulco G, Casapullo A, Debitus C, Gomez-Paloma L, Riccio R. Eur. J. Org. Chem. 2001:775–778. doi: 10.1021/np010053+. [DOI] [PubMed] [Google Scholar]
  • 95.Lee K, Kim H, Hong J. Angew. Chem. Int. Ed. 2012;51:5735–5738. doi: 10.1002/anie.201201653. [DOI] [PubMed] [Google Scholar]
  • 96.Kharasch MS, Joshi BS. J. Org. Chem. 1957;22:1439–1443. [Google Scholar]
  • 97.Maki BE, Chan A, Phillips EM, Scjheidt KA. Tetrahedron. 2009;65:3102–3109. doi: 10.1016/j.tet.2008.10.033. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES